Zoetis Inc.

Is Zoetis owned by Pfizer?
No. Zoetis was Pfizer's animal health division until 2013, when Pfizer spun it off through an IPO and a subsequent exchange offer distributing its remaining stake to shareholders. Zoetis has been fully independent since June 2013 and Pfizer holds no ownership interest.

Is Zoetis publicly traded?
Yes. Zoetis trades on the New York Stock Exchange under ticker ZTS and is a member of the S&P 500. Its February 2013 IPO raised about $2.2 billion.

What does Zoetis sell?
Medicines, vaccines, and diagnostics for companion animals and livestock. Best-known products include Apoquel and Cytopoint for dog dermatology, Simparica Trio for parasite protection, Librela and Solensia for arthritis pain, Revolution for cats and dogs, and Draxxin for cattle respiratory disease.

What was Zoetis' revenue in 2025?
FY2025 revenue was $9.5 billion, up 6 percent on an organic operational basis, with net income of $2.7 billion. Revenue in Q3 2026 was $2.4 billion, down 1 percent year over year amid new dermatology competition and generic pressure.

What is Librela and why is it controversial?
Librela is the first monoclonal antibody approved to control osteoarthritis pain in dogs. Reports of adverse events in some treated dogs led to label updates and regulatory review starting in 2024, slowing adoption. Zoetis maintains the product's benefit-risk profile is positive based on surveillance across millions of treated animals.

Where is Zoetis headquartered?
Parsippany-Troy Hills, New Jersey, USA. The company was formed from Pfizer's animal health division in 2012 and completed its separation from Pfizer in 2013.

The business inside Zoetis is far older than the company name. Pfizer entered animal health in 1952, when its blockbuster antibiotic Terramycin found a market treating livestock disease. Through the second half of the twentieth century, Pfizer Animal Health grew into one of the industry's largest units, adding vaccines, parasiticides, and anti-infectives through research and bolt-on deals.

Landmark products accumulated over decades. Rimadyl, launched in 1997, became the first widely adopted NSAID for canine arthritis and created the modern pain-management category in dogs. Revolution arrived in 1999 as a pioneering topical parasiticide. Draxxin gave cattle producers a long-acting respiratory antibiotic, and the Vanguard line anchored the vaccine portfolio. By the late 2000s, Pfizer Animal Health was the largest animal health business in the world.

Pfizer's strategic review after the Wyeth acquisition put the unit on the block. In 2012, Pfizer announced the separation and chose a new name: Zoetis, derived from "zoetic," relating to life. The February 2013 IPO raised approximately $2.2 billion, then the largest U.S. IPO since Facebook. Pfizer completed the separation in June 2013 through a tax-free exchange offer that distributed its remaining roughly 80 percent stake to shareholders.

Independence under founding CEO Juan Ramón Alaix let the company act like a specialist. It trimmed commodity lines, bought Abaxis in 2018 for approximately $2 billion to enter point-of-care veterinary diagnostics through the Vetscan platform, and built the industry's largest companion animal portfolio. Alaix retired at the end of 2019; Kristin Peck, a Pfizer veteran who had led the spin-off, became CEO in January 2020.

The 2020s cemented Zoetis as an innovator rather than a generics shop. Simparica Trio launched in the United States in 2020 and became the world's top canine parasiticide, passing $1 billion in U.S. sales in 2025. The company pioneered monoclonal antibodies in veterinary medicine: Cytopoint in 2016, then Librela for dogs (U.S. approval May 2023) and Solensia for cats (U.S. approval January 2022), the first mAb pain therapies of their kind. Apoquel added a chewable formulation in 2024 that quickly grew to roughly half of the brand's volume.

Portfolio shaping continued. Zoetis sold its medicated feed additive portfolio to Phibro Animal Health in 2024, acquired Australian veterinary pharmaceutical maker Jurox in 2022 and antibody developer PetMedix in 2023, and bought imaging teleradiology provider VitalRADS in 2026 to expand diagnostics.

The challenge entering late 2026 is competitive pressure. New entrants took share in dermatology, generics eroded older brands, and Librela faced safety-perception headwinds after adverse-event reports drew regulatory attention. Q3 2026 revenue of $2.4 billion fell 1 percent year over year, with the U.S. segment down sharply in key dermatology while international markets and diagnostics grew.

Zoetis publishes an annual sustainability report organized around animal welfare, environmental footprint, and workforce. Headline commitments include renewable electricity procurement at major sites, packaging reduction, and antibiotic stewardship in livestock, where it supports veterinary oversight of medically important antimicrobials.

The company's products sit inside the animal welfare debate from two directions. Livestock medicines and vaccines support food-animal production, which critics link to factory farming and antimicrobial resistance; Zoetis counters that healthy animals reduce the footprint of protein production and that it has removed growth-promotion claims from medically important antibiotics. On the companion animal side, the business aligns with welfare goals directly.

Librela and Solensia have drawn the sharpest scrutiny. Post-market adverse-event reports on the canine OA mAb led to label updates and regulator communications to veterinarians, pressuring adoption through 2025 and 2026. Zoetis maintains the products' benefit-risk profiles remain positive, citing post-market surveillance data across millions of treated animals.

Zoetis is a fixture on the Fortune 500 and S&P 500 and has appeared on Forbes lists of leading employers and innovative companies. Its products regularly win veterinary industry recognition: Librela's approval was the first licensed monoclonal antibody for a companion animal condition in the United States, and Simparica Trio's triple-combination launch was named among the most successful companion animal introductions in industry history. The company's Kansas City and European R&D operations hold ISO certifications supporting its quality systems.

The dominant controversy is Librela safety. Beginning in 2024, owner reports of adverse neurological and musculoskeletal events in dogs treated with the OA pain mAb circulated widely, prompting regulatory review and a label update in the United States and the European Union. Zoetis defended the product, noting adverse-event rates within expected ranges across millions of doses, but conceded the perception headwind slowed new patient starts through 2026.

Antibiotic use in livestock is a standing policy issue. Regulators in the U.S. and EU have tightened rules on medically important antimicrobials, and Zoetis has reformulated labeling and stewardship programs accordingly; the 2024 sale of its medicated feed additive portfolio also reduced that exposure.

Earlier in its history, ProHeart 6 was voluntarily withdrawn from the U.S. market in 2004 over safety concerns and returned in 2008 with revised labeling and monitoring requirements, an episode the company cites as precedent for transparent post-market management.